{"schema_version":"secwatch.filing_event.v1","accession":"0001562762-23-000046","form_type":"8-K","ticker":"GMED","cik":"0001237831","company_name":"GLOBUS MEDICAL INC","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.136913+00:00","generated_at":"2026-06-19T06:30:39.516424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Globus Medical Q4 net sales $274.5M (+9.8% YoY); full year exceeds $1B; guides 2023 sales $1.1B","bullets":["Q4 GAAP diluted EPS $0.49, non-GAAP diluted EPS $0.59; net income $50.1M (+231% YoY).","Full year 2022 net sales $1,022.8M (+6.8% YoY); GAAP diluted EPS $1.85, non-GAAP $2.06.","Non-GAAP adjusted EBITDA Q4 $90.2M (32.8% of sales); full year $339.2M (33.2%).","2023 guidance: net sales ~$1.1B, non-GAAP diluted EPS $2.30.","Company remains debt-free; net cash from ops $178.5M, free cash flow $104.4M for full year."],"urls":{"canonical":"https://secwatch.observer/filing/0001562762-23-000046","json":"https://secwatch.observer/filing/0001562762-23-000046.json","markdown":"https://secwatch.observer/filing/0001562762-23-000046.md","text":"https://secwatch.observer/filing/0001562762-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000046/0001562762-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000046/gmed-20230221x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:30:39.516424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e7417ab793c41fad9e5e9e1018b66767ec1e2edf","claim":"GLOBUS MEDICAL INC reported Full Year 2022 results: revenue $1,022.8 million, net income $190.2 million, EPS $1.85.","evidence_excerpt":"Full Year 20 2 2 : · Worldwide net sales were $ 1,022.8 million , an increase of 6.8 % , or 8.2% on a constant currency basis · GAAP n et income for the year was $ 1 90.2 million · GAAP d iluted EPS was $ 1. 85 and n on-GAAP diluted EPS was $ 2.0 6 · Non-GAAP adjusted EBITDA was $ 33 9.2 million, or 3 3.2 % of net sales","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1237831/000156276223000046/0001562762-23-000046-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2022"},{"label":"Revenue","value":"$1,022.8 million"},{"label":"Net income","value":"$190.2 million"},{"label":"EPS","value":"$1.85"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}